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ABSTRACT
Resistant hypertension (RH) is associated with organ damage and cardiovascular risk (CV). Evidences suggest the involvement of matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in hypertension and in CV remodeling. The aim of this study was assess the levels of MMP-2 and TIMP-2 in resistant hypertension and its relation with organ damage, including arterial stiffness and cardiac hypertrophy. MMP-2 and TIMP-2 levels were compared among 19 normotensive (NT), 116 non-resistant hypertensive (HT) and 116 resistant hypertensive (RH) subjects. MMP-2 levels showed no differences among NT, HT and RH groups, while TIMP-2 levels were higher in RH compared to HT and NT (90.0 (76.1-107.3) vs. 70.1 (57.7-88.3) vs.54.7 (40.9-58.1)ng/mL, p<0.01), respectively. MMP-2/TIMP-2 ratio was reduced in RH group compared to HT and NT subjects (2.7 (1.9-3.4) vs.3.3 (2.6-4.2) vs.4.9 (4.5-5.3), p<0.01), respectively. No associations were found between MMP-2 levels, TIMP-2 and MMP-2/TIMP-2 ratio with cardiac hypertrophy and arterial stiffness in resistant and non-resistant group. However TIMP-2 levels were associated with LVMI in total hypertensive group (r= 0.16, p=0.02). Finally, in a regression analysis reduced MMP-2/TIMP-2 ratio and increased TIMP-2 levels were independently associated with RH. The present findings provide evidence that TIMP-2 is associated with resistant hypertension and might be a possible biomarker for screening resistant hypertension subjects.
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INTRODUCTION
Resistant hypertension (RH) is a multifactorial condition associated with mortality  HYPERLINK \l "_ENREF_1" \o "Fatemi, 2016 #180"  ADDIN EN.CITE <EndNote><Cite><Author>Fatemi</Author><Year>2016</Year><RecNum>180</RecNum><record><rec-number>180</rec-number><foreign-keys><key app="EN" db-id="t05r0vrvx0z5tpesr275dvvmxdw0dpzpdev2">180</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Fatemi, O.</author><author>Goa, C.</author><author>Faselis, C.</author><author>Kokkinos, P.</author><author>Papademetriou, V.</author></authors></contributors><auth-address>George Washington University Hospital, Washington, DC.&#xD;Georgetown University Hospital, Washington, DC.&#xD;Veterans Affairs Medical Center, Washington, DC.&#xD;Washington Hospital Center, Washington, DC.&#xD;George Washington University School of Medicine, Washington, DC.&#xD;Georgetown University School of Medicine, Washington, DC.&#xD;Washington DC VA Medical Center, Washington, DC.</auth-address><titles><title>Improvement in All-Cause Mortality With Blood Pressure Control in a Group of US Veterans With Drug-Resistant Hypertension</title><secondary-title>J Clin Hypertens (Greenwich)</secondary-title></titles><pages>33-9</pages><volume>18</volume><number>1</number><edition>2015/10/07</edition><dates><year>2016</year><pub-dates><date>Jan</date></pub-dates></dates><isbn>1751-7176 (Electronic)&#xD;1524-6175 (Linking)</isbn><accession-num>26440866</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/26440866</url></related-urls></urls><electronic-resource-num>10.1111/jch.12672</electronic-resource-num><language>eng</language></record></Cite></EndNote>1, greater risk of cardiovascular events  HYPERLINK \l "_ENREF_2" \o "Daugherty, 2012 #3"  ADDIN EN.CITE <EndNote><Cite><Author>Daugherty</Author><Year>2012</Year><RecNum>3</RecNum><record><rec-number>3</rec-number><foreign-keys><key app="EN" db-id="t05r0vrvx0z5tpesr275dvvmxdw0dpzpdev2">3</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Daugherty, S. L.</author><author>Powers, J. D.</author><author>Magid, D. J.</author><author>Tavel, H. M.</author><author>Masoudi, F. A.</author><author>Margolis, K. L.</author><author>O&apos;Connor, P. J.</author><author>Selby, J. V.</author><author>Ho, P. M.</author></authors></contributors><auth-address>Division of Cardiology, University of Colorado-Denver, 12605 E 16th Ave., Aurora, CO 80045, USA. stacie.daugherty@ucdenver.edu</auth-address><titles><title>Incidence and prognosis of resistant hypertension in hypertensive patients</title><secondary-title>Circulation</secondary-title><alt-title>Circulation</alt-title></titles><pages>1635-42</pages><volume>125</volume><number>13</number><edition>2012/03/02</edition><keywords><keyword>Cohort Studies</keyword><keyword>Female</keyword><keyword>Follow-Up Studies</keyword><keyword>Humans</keyword><keyword>Hypertension/*diagnosis/*epidemiology/therapy</keyword><keyword>Incidence</keyword><keyword>Male</keyword><keyword>Middle Aged</keyword><keyword>Prognosis</keyword><keyword>Retrospective Studies</keyword></keywords><dates><year>2012</year><pub-dates><date>Apr 3</date></pub-dates></dates><isbn>1524-4539 (Electronic)&#xD;0009-7322 (Linking)</isbn><accession-num>22379110</accession-num><work-type>Comparative Study&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.</work-type><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/22379110</url></related-urls></urls><custom2>3343635</custom2><electronic-resource-num>10.1161/CIRCULATIONAHA.111.068064</electronic-resource-num><language>eng</language></record></Cite></EndNote>2 and higher incidence of target organ damage  ADDIN EN.CITE 3-4. Target organ damage in RH is closely associated with the lack of blood pressure (BP) control and cardiovascular remodeling  ADDIN EN.CITE 3, 5. It requires the activation of intracellular pathways that lead to (i) proliferation, migration and apoptosis of cells and (ii) synthesis and degradation of extracellular matrix (ECM) proteins of cardiac and vascular tissues  ADDIN EN.CITE 6-8. 
Closely linked to the ECM reorganization, the matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that degrade several proteins at cardiac and vascular tissues. The activity of the MMPs is affected by endogenous inhibitors, such as tissue inhibitors of metalloproteinases (TIMP) and alpha-2-macroglobulin (A2M), a non-specific inhibitor of circulating proteases. Therefore, the balance between MMPs and inhibitors are essential for the extracellular matrix remodeling in tissues  HYPERLINK \l "_ENREF_9" \o "Nagase, 2006 #53"  ADDIN EN.CITE <EndNote><Cite><Author>Nagase</Author><Year>2006</Year><RecNum>53</RecNum><record><rec-number>53</rec-number><foreign-keys><key app="EN" db-id="t05r0vrvx0z5tpesr275dvvmxdw0dpzpdev2">53</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Nagase, H.</author><author>Visse, R.</author><author>Murphy, G.</author></authors></contributors><auth-address>Department of Matrix Biology, Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College London, 1 Aspenlea Road, London W6 8LH, UK. h.nagase@imperial.ac.uk</auth-address><titles><title>Structure and function of matrix metalloproteinases and TIMPs</title><secondary-title>Cardiovasc Res</secondary-title><alt-title>Cardiovascular research</alt-title></titles><pages>562-73</pages><volume>69</volume><number>3</number><edition>2006/01/13</edition><keywords><keyword>Animals</keyword><keyword>Cardiovascular Diseases/enzymology</keyword><keyword>Cardiovascular System/*enzymology</keyword><keyword>Extracellular Matrix/*enzymology</keyword><keyword>Humans</keyword><keyword>Matrix Metalloproteinase Inhibitors</keyword><keyword>Matrix Metalloproteinases/*chemistry</keyword><keyword>Structure-Activity Relationship</keyword><keyword>Tissue Inhibitor of Metalloproteinases/*chemistry/metabolism</keyword></keywords><dates><year>2006</year><pub-dates><date>Feb 15</date></pub-dates></dates><isbn>0008-6363 (Print)&#xD;0008-6363 (Linking)</isbn><accession-num>16405877</accession-num><work-type>Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review</work-type><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/16405877</url></related-urls></urls><electronic-resource-num>10.1016/j.cardiores.2005.12.002</electronic-resource-num><language>eng</language></record></Cite></EndNote>9. 
Gelatinases, such as MMP-2 and MMP-9, have been associated with hypertension and target organ damage  ADDIN EN.CITE 10-11. MMP-2 expression is up-regulated in cardiac cells in response to many elements such as angiotensin II, endothelin-1, pro-inflammatory cytokines, hormones and growth factors 12. It has a role in cleaving ECM molecules, elastin and type IV collagen and digests interstitial collagen types I, II and II9. In addition, MMP-2 is highly expressed in almost all cardiac cells and can be activated by oxidative stress13. Therefore, MMP-2 is one of the most studied MMPs in essential hypertension. Nonetheless, the relation between MMP-2 and TIMP-2 levels in RH remains unclear. The aim of this study was assess the levels of MMP-2 and TIMP-2 in RH and its association with target-organ damage (arterial stiffness and cardiac hypertrophy). 
METHODS
Subjects and Study Design
For this cross-sectional study, resistant hypertensive (RH) patients regularly followed at the Resistant Hypertension Clinic of the University of Campinas (Campinas, Brazil) and non-resistant hypertensives (HT), followed at the Hypertension Clinic of Valinhos (Brazil) were screened. The study was conducted at the aforementioned center, reviewed and approved by the IRB (IRB from the School of Medical Sciences of University of Campinas, Campinas-Brazil/ Approval number 188.161/2013) and conducted in accordance with the Declaration of Helsinki Principles. In addition, written informed consent was obtained from all participants. 
Inclusion and exclusion criteria
The inclusion criteria were: i) Diagnosis of non-resistant or resistant hypertension ADDIN EN.CITE 14; ii) Age between 18-65 years; iii) Volunteer participation and informed consent signature; iv) Regular follow-up for at least six months; v) Previous proven adherence to non-pharmacological and pharmacological treatment; vi) Women in reproductive phase must be under use of contraception methods.
After 6-months of follow-up, patients were properly diagnosed as having RH or HT. RH was defined as BP that remained above the target pressure (≥140/90 mmHg), despite the use of three or more different classes of antihypertensive drugs at optimal doses or controlled BP with the use of four or more antihypertensive drugs  ADDIN EN.CITE 15. To identify true resistance to treatment and exclude white-coat hypertension, pseudoresistance, lack of medication adherence, and secondary forms of hypertension, RH subjects were submitted to drug therapy optimization and pill counts, office blood pressure (BP), ambulatory blood pressure monitoring (ABPM) measurements  ADDIN EN.CITE 15, imaging and biochemical exams. The HT subjects were defined as all hypertensive subjects without resistance to treatment  ADDIN EN.CITE 14.
 In regard to the exclusion criteria, the following point were taken into account:  i) Medical history or clinical symptoms of heart failure (ejection fraction < 50%); ii) Presence of cardiomyopathy; iii) Valvular or pericardial heart diseases; iv) Diagnosis of cerebrovascular disease or peripheral vascular disease; v) Nephropathy; vi) Liver dysfunction; vii) Autoimmune diseases; viii) Pregnancy or declared intention to become pregnant.
All hypertensive volunteers were recruited consecutively and were divided into two groups: HT (n=116) and RH (n=116), according to the above-mentioned criteria (Figure 1). Nineteen normotensive subjects (NT) were randomly selected to be included as the control group (n=19). 
Blood pressure measurements
To determine office systolic BP (SBP) and diastolic BP (DBP) a trained health professional performed at least three measurements with a 3-minute interval. Subjects were monitored in a seated position after a 10-minute rest, approximately at 8:00 a.m., using a digital BP monitor (OMRON Healthcare Inc., Bannockburn, IL, USA). 
ABPM was used to exclude pseudoresistance hypertension through twenty-four hour BP monitoring by an automatic oscillometric device (Spacelabs 90207, Spacelabs Inc, Redmon, WA, USA). BP was measured automatically at a 20-min interval during 24-h period and subjects were instructed to keep their normal daily activities and take notes of their sleep period in a personal diary16. 
Aortic pulse wave velocity measurement
	Pulse wave velocity (PWV) measurements were obtained through Sphygmocor system (Artcor, Sidney, Australia) and used to estimate arterial stiffness. The pulse waves were obtained via transcutaneous using a tonometer at the right common carotid and femoral arteries. PWV was calculated as the ratio of the distance (meters)/Δt (seconds) between the femoral recording site and the supra-sternal notch minus the distance from the supra-sternal notch to the carotid recording site  HYPERLINK \l "_ENREF_17" \o "Van Bortel, 2012 #58"  ADDIN EN.CITE <EndNote><Cite><Author>Van Bortel</Author><Year>2012</Year><RecNum>58</RecNum><record><rec-number>58</rec-number><foreign-keys><key app="EN" db-id="t05r0vrvx0z5tpesr275dvvmxdw0dpzpdev2">58</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Van Bortel, L. M.</author><author>Laurent, S.</author><author>Boutouyrie, P.</author><author>Chowienczyk, P.</author><author>Cruickshank, J. K.</author><author>De Backer, T.</author><author>Filipovsky, J.</author><author>Huybrechts, S.</author><author>Mattace-Raso, F. U.</author><author>Protogerou, A. D.</author><author>Schillaci, G.</author><author>Segers, P.</author><author>Vermeersch, S.</author><author>Weber, T.</author></authors></contributors><auth-address>Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium.</auth-address><titles><title>Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity</title><secondary-title>J Hypertens</secondary-title><alt-title>Journal of hypertension</alt-title></titles><pages>445-8</pages><volume>30</volume><number>3</number><edition>2012/01/27</edition><keywords><keyword>Carotid Arteries/physiology</keyword><keyword>*Diagnostic Techniques, Cardiovascular</keyword><keyword>Femoral Artery/physiology</keyword><keyword>Humans</keyword><keyword>Pulse</keyword><keyword>*Vascular Stiffness</keyword></keywords><dates><year>2012</year><pub-dates><date>Mar</date></pub-dates></dates><isbn>1473-5598 (Electronic)&#xD;0263-6352 (Linking)</isbn><accession-num>22278144</accession-num><work-type>Practice Guideline</work-type><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/22278144</url></related-urls></urls><electronic-resource-num>10.1097/HJH.0b013e32834fa8b0</electronic-resource-num><language>eng</language></record></Cite></EndNote>17. Three consecutive readings were collected to determine the PWV average value that was used in analyses.
Echocardiography
The dimensions of the left ventricle (LV) - diastolic and systolic LV diameters, interventricular septal and posterior wall thicknesses – were measured at the end of diastole using the 2-dimensional targeted M-mode, and LV mass was calculated by the Devereux formula, according to the recommendations of the American Society of Echocardiography  ADDIN EN.CITE 18. LVMI was calculated by dividing the LV mass by the body surface area. Echocardiographic measurements were performed by two blinded investigators, using cardiovascular ultrasound machine (Siemens Acuson CV70, Munich, Bavaria, Germany) with multi-frequency sector transducer (2-4MHz). 
Biochemical measurements
Blood samples were collected at early morning after an overnight fasting. Plasma aldosterone was measured by radioimmunoassay (Immunotech SAS, Marseille, France) according to the manufacturer’s instructions.  Urine albumin-to-creatinine ratio (mg/g) was used to evaluate microalbuminuria. Subjects presenting values lower than 30mg/g were classified as normal and microalbuminuria was classified at values between 30 and 300mg/g classified. 
MMP-2 and TIMP-2 measurements
Heparin-anticoagulated blood samples were obtained after an overnight fasting period by venipuncture. The blood samples were centrifuged and plasma samples were immediately stored at -80ºC. MMP-2 and TIMP-2 were measured by enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Inc., Minneapolis, USA) according to the manufacturer's instructions.
Statistical analysis
Descriptive statistics were described as mean ± standard deviation or median and 1st, 3rd quartiles, according to data distribution. The data distribution was assessed by Shapiro-Wilk test. Continuous variables in all groups were compared by one-way ANOVA. Mann-Whitney test was performed to compare nonparametric continuous variables, and Fisher’s test for categorical variables. Correlation analyses were performed by Spearman’s correlation coefficient. Logistic regression analyses evaluated the association of MMP-2, TIMP-2 and MMP-2/TIMP-2 ratio, adjusted for potential confounders, with the presence of resistance to treatment. Finally, a given probability of type I error (α) of 0.05 was considered and a power (1 − β) of 0.9 for TIMP-2 analyses.

RESULTS
The general characteristics and biochemical parameters of NT, HT and RH groups are shown in Table 1 and Table 2, respectively. RH subjects presented higher left ventricular mass index, lower pulse-wave velocity, higher microalbuminuria, higher cholesterol and LDL levels, higher HBA1c, glucose, microalbuminuria, C-reactive protein and aldosterone levels compared to HT group. The NT group shown biochemical levels lower compared to HT group. Correlation analyses revealed no associations between aldosterone/renin ratio and TIMP-2, MMP-2 and MMP-2/TIMP-2 in either all hypertensive groups (RH+HT) or RH group (data not shown).
As expected, higher number of antihypertensive drugs were used in RH (4 ± 1) compared to HT (2 ± 1) – table 3. No statistical differences in MMP-2 levels were observed among NT, HT and RH groups (240.1 (191.2-308.4) vs. 237.0 (197.2-276.6) vs. 228.9 (203.9-293.5) ng/mL, p=0.65), respectively (figure 2A). On the other hand, increased TIMP-2 levels were detected in RH compared to HT and NT (90.0 (76.1-107.3) vs. 70.1 (57.7-88.3) vs. 54.7 (40.9-58.1) ng/mL, p< 0.01), respectively (figure 2B). In addition, lower MMP-2/TIMP-2 ratio was found in RH group compared with HT and NT (2.7 (1.9-3.4) vs. 3.3 (2.6-4.2) vs. 4.9 (4.5-5.3), p< 0.01), respectively (figure 2C). 
Due to the higher prevalence of target organ damage (TOD) in RH and its association with increased mortality, we evaluated MMP-2 and TIMP-2 levels in both hypertension groups and the association of plasma levels with cardiac hypertrophy and arterial stiffness (well-known hypertension-induced targets organ damage). However, after correlation analysis, no associations were found between  PWV and LVMI (reflecting arterial stiffness and cardiac hypertrophy) with MMP-2, TIMP-2, and MMP-2/TIMP-2 ratio in HT or RH groups (table 4 and 5). On the other hand, correlation analysis combining both hypertensive groups (HT+RH) revealed a positive correlation between TIMP-2 and LVMI (table 6).  
A correlation analysis among MMP-2, TIMP-2, MMP-2/TIMP-2 ratio and ambulatory BP measurements (systolic and diastolic) in the hypertensive groups (RH+HT) were performed. While TIMP-2 showed no significant correlation with systolic and diastolic ABPM values, a significant correlation between MMP-2/TIMP-2 and systolic ABPM (r=0.15, p=0.03) was detected. In addition, a correlation between MMP-2 levels with both systolic (r= 0.24, p<0.01) and diastolic ABPM (r=0.15, p= 0.04) was also found. 
Finally, the different models of logistic regression demonstrated that TIMP-2 levels and MMP-2/TIMP-2 ratio were independently associated with resistance to antihypertensive treatment, after adjustment for age, gender, aldosterone levels, presence of diabetes, body mass index and race (table 7). The same results were observed when the logistic regression was performed including the normotensive group (NT+HT+RH) (TIMP-2 Odds ratio 1.04 (1.02-1.05, 95%CI), p<0.01; and MMP-2/TIMP-2 Odds ratio 0.64 (0.49-0.84, 95%CI), p<0.01.

            	DISCUSSION
In this study we found higher levels of TIMP-2 and also lower MMP-/TIMP-2 ratio in RH subjects compared to HT and normotensive subjects. Interestingly, MMP-2 levels were similar among all strata of hypertension studied. Also, high TIMP-2 levels and low MMP-2/TIMP-2 ratio were independently associated with resistance to treatment in RH subjects. Also, TIMP-2 levels were correlated with LVMI in total hypertension group, but not in resistant hypertensive patients. A review of the literature was performed at Pubmed and Web of science and to the best of our knowledge, this is the first study comparing MMP-2 and TIMP-2 levels among normotensive, non-resistant and resistant hypertensive subjects.
TIMP-2 levels have been reported to be unchanged in hypertensives compared to control subjects  ADDIN EN.CITE 19-21. More conflicting findings have been reported on MMP-2 levels in hypertension. Some studies found increased  ADDIN EN.CITE 22-23, decreased  ADDIN EN.CITE 24-25 and even unchanged MMP-2 levels  ADDIN EN.CITE 20-21 in hypertension. This inconsistence may be justified by the differences in (i) study designs, (ii) methods of measurement (ELISA, immunohistochemistry or zymography), (iii)  study population and the presence of comorbidities and target organ damage  ADDIN EN.CITE 20, 26-27, and (iv) statistical power. 
MMP-2 is expressed in almost all cardiac cells. It is activated by oxidative stress injury and in long-term and chronic processes may transform into an irreversible injury. Recently, an interesting study showed the influence of MMP-2 levels in both animal and human cardiovascular disease  ADDIN EN.CITE 28, suggesting MMPs as potential therapeutic targets in myocardial diseases  ADDIN EN.CITE 29. Although some data show increased MMP-2 levels in myocardial diseases, one study found decreased levels in hypertensive patients with LV hypertrophy. The low levels support that such alteration may contribute to the phenotypic and structural changes in the hypertensive heart disease  ADDIN EN.CITE 20. 
Experimental and clinical studies have shown the influence of TIMP-2 levels in cardiac remodeling. For instance, it has been shown that TIMP-2 deficiency is related to exacerbated LV dilation and dysfunction ADDIN EN.CITE 30-32. Such scarcity impairs cardiac function, since TIMP-2 is required for optimal structure and function following biomechanical stress 33. On the other hand, it was reported that TIMP-2 increases collagen synthesis  ADDIN EN.CITE 34 and also stimulates cardiac fibroblast proliferation and differentiation into myofibroblasts, contributing to the mature collagen matrix formation HYPERLINK \l "_ENREF_28" \o "Vanhoutte, 2006 #156"  ADDIN EN.CITE <EndNote><Cite><Author>Vanhoutte</Author><Year>2006</Year><RecNum>156</RecNum><record><rec-number>156</rec-number><foreign-keys><key app="EN" db-id="t05r0vrvx0z5tpesr275dvvmxdw0dpzpdev2">156</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Vanhoutte, D.</author><author>Schellings, M.</author><author>Pinto, Y.</author><author>Heymans, S.</author></authors></contributors><auth-address>Molecular and Vascular Biology and Center for Transgene Technology and Gene Therapy, University of Leuven, Belgium.</auth-address><titles><title>Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window</title><secondary-title>Cardiovasc Res</secondary-title><alt-title>Cardiovascular research</alt-title></titles><pages>604-13</pages><volume>69</volume><number>3</number><edition>2005/12/20</edition><keywords><keyword>Animals</keyword><keyword>Extracellular Matrix/*enzymology</keyword><keyword>Matrix Metalloproteinase Inhibitors</keyword><keyword>Matrix Metalloproteinases/*metabolism</keyword><keyword>Mice</keyword><keyword>Mice, Transgenic</keyword><keyword>Myocardial Infarction/*enzymology</keyword><keyword>Time Factors</keyword><keyword>Tissue Inhibitor of Metalloproteinases/*metabolism</keyword><keyword>Ventricular Remodeling</keyword></keywords><dates><year>2006</year><pub-dates><date>Feb 15</date></pub-dates></dates><isbn>0008-6363 (Print)&#xD;0008-6363 (Linking)</isbn><accession-num>16360129</accession-num><work-type>Research Support, Non-U.S. Gov&apos;t&#xD;Review</work-type><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/16360129</url></related-urls></urls><electronic-resource-num>10.1016/j.cardiores.2005.10.002</electronic-resource-num><language>eng</language></record></Cite></EndNote>35. In addition, increased TIMP-2 levels were found in subjects with hypertrophic cardiomyopathy  ADDIN EN.CITE 36, suggesting that TIMP-2 levels may reflect an adaptive response to dampen the elevated proteolytic activity that occurs in heart disease  ADDIN EN.CITE 31. 
The literature shows controversial associations between MMP-2 and TIMP-2 levels and TOD. The high prevalence of TOD is a well known feature in RH, however no associations were found between arterial stiffness and left ventricular mass index with MMP-2, TIMP-2, and MMP-2/TIMP-2 ratio in both antihypertensive groups analyzed separately (resistant and non-resistant). Interestingly, a positive correlation was observed between TIMP-2 levels and LVMI in the total group (HT +RH). It may suggest a compensatory response of the CV remodeling in an attempt of control MMP-2 activity and minimize CV damage in hypertension. Although MMP-2 levels were similar among RH and HT groups, the decreased ratio observed in RT might reflect lower activity of MMP-2. TIMP-2 binds to MMP-2 inhibiting its proteolytic activity, thus the MMP-2/TIMP-2 ratio is also an important index for assessing MMP-2 activity. Interestingly, the MMP-2/TIMP-2 ratio was decreased in RH, which might indicate a reduced global action of the MMP-2 enzyme. 
Logistic regression analysis revealed that TIMP-2 levels, but not MMP-2 levels, is significant independently associated with resistant hypertension in an adjusted analysis for the well-described risk factors for RH (age, gender, race, diabetes, body mass index, aldosterone levels).  Moreover, the RH group was divided in white and non-white and obese and non-obese, to analyze the influence in TIMP-2 levels. No differences were found in TIMP-2 levels according to race and BMI, which strengths the association between high TIMP-s levels and RH found in the current study.
	We have shown in this study that TIMP-2 is a significant predictor for resistant hypertension. Considering the lack of correlation between TIMP-2 and ambulatory BP (RH+HT) this finding may not represent a continuum of BP and TIMP-2 levels may represent an important role in the pathophysiology if RH. Despite resistant and non-resistant hypertension represent distinct conditions, systolic and diastolic ABPM values were similar between hypertensive groups in this study.  Interestingly, MMP-2 levels and MMP-2/TIMP-2 were positively correlated with ABPM, suggesting that MMP-2 is associated with BP in a continuum manner but not with RH phenotype. Although it might sounds a sort of paradox, these findings lead to the interpretation that RH represent a distinct hypertensive phenotype. TIMP-2 levels are associated with RH phenotype and might be explored as a possible biomarker of this condition in the further studies.
In spite of reaching interesting findings, our study has some drawbacks. i) The possible influence of multiple antihypertensive drugs is an intrinsic limitation of studies on resistant hypertension. Some drugs as antihypertensive may affect MMP concentrations  ADDIN EN.CITE 37-38, as well as statins  ADDIN EN.CITE 39-40, acetylsalicylic acid  ADDIN EN.CITE 41-42 and some diuretics as spironolactone and hydrochlorothiazide  ADDIN EN.CITE 43. Multiple linear regression showed no association between TIMP-2 levels and anti-hypertensive medication, statins, acetylsalicylic acid and anti-diabetics. Thus, the medication might not affect our results; ii) Since the analysis of aldosterone/renin ratio was performed only in a subset of RH (n=72) and HT (n=17), our negative finds might be underestimated; iii) The sample size is not large enough to ensure more robust inferences; iv) The low power of the study in MMP-2 analyses. Finally, this is a cross-sectional study and cause-effect relationship cannot be inferred. Therefore, further studies with different designs, such as RCTs or cohorts, are needed to clarify some points and also to strength our findings.
Our regression analysis model included well-known factors that contribute to increased risk for resistant hypertension. In spite of that, we were still able to detect a significant association between TIMP-2 and resistant hypertension
To sum up, RH was associated with higher TIMP-2 levels and low MMP-2/TIMP-2 ratio, suggesting that these regulators of ECM remodeling play a key role in BP control in this high-risk subset of hypertensive individuals. These findings provide evidence that TIMP-2 is associated with resistant hypertension and might be a candidate risk biomarker for resistant hypertension.
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Table 1 – General characteristics of normotensive subjects, non-resistant hypertensive and resistant hypertensive subjects 
Variables	NT (n=19)	HT (n=116)	RH (n=116)	p-value
Age (years)	52 ± 5	62 ± 9 *	60 ± 10 *	<0.01
Female gender %	47	60	66	0.25
Black Race %	---	15 	43 #	<0.01
Diabetes %	---	35 	52 #	0.02
BMI (Kg/m2)	25.0 (23.1-27.0)	27.7 (24.9-31.7) *	31.2 (27.0-34.9) *#	<0.01
Waist/Hip ratio	---	0.91 (0.86-0.97)	0.94 (0.88-0.99) #	0.04
Office SBP (mmHg)	119 (111-134)	139 (130-148) *	146 (134-158) *#	<0.01
Office DBP (mmHg)	80 (72-86)	82 (78-86)	82 (76-91)	0.19
Office HR (bpm)	64 (60-70)	67 (61-77)	66 (58-74)	0.19
ABPM SBP (mmHg) 	---	127 (121-135)	129 (116-141)	0.40
ABPM DBP (mmHg) 	---	77 (72-82)	76 (70-84)	0.75
LVMI (g/m2)	---	96.3 (86.4-113.0) 	115.1 (95.0-142.0) #	   <0.01
PWV (m/s)	7.1 (6.5-7.7)	9.4 (8.4-11.3)*	9.1 (7.6-11.1)*	<0.01
Data expressed as mean ± SD or median (1st, 3rd quartiles). NT= normotensive; HT= non-resistant hypertensive; RH = resistant hypertensive; N = sample size; F = female; BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; ABPM = ambulatory blood pressure monitoring; LVMI = left ventricular mass index; PWV = Pulse wave velocity. * p<0.05 vs. NT ; p< 0.05 # vs. HT


Table 2 - Biochemical parameters of normotensive subjects, non-resistant hypertensive and resistant hypertensive subjects
Variables	NT (n=19)	HT (n=116)	RH (n=116)	p-value
Total Cholesterol (mg/mL)	193 (179-215)	165 (136-186) *	180 (148-208) *#	<0.01
LDL (mg/mL)	112 (93-133)	85 (66-107) *	97 (77-127) #	<0.01
HDL (mg/mL)	47 (40-56)	49 (42-58)	45 (38-53) #	0.02
Hb A1c (%)	5.2 (5.1-5.3)	6.0 (5.7-6.4) *	6.3 (6.0-7.8) *#	<0.01
Triglycerides	134 (97-154)	115 (80-157)	130 (95-192) 	0.08
Glucose (mg/mL)	82.2 (80.0-88.0)	97 (90-107) *	101 (89-136) *	<0.01
Creatinine (mg/mL)	0.9 (0.8-1.0)	0.9 (0.8-1.1)	1.0 (0.8-1.2)	0.08
Microalbuminuria (mg/g)	6.7 (3.5-9.3) n=19	5.8 (3.8-12.6) n=34	13.2 (7.6-45.9) n=74 *#	<0.01
C-reactive protein (mg/dL)	0.09 (0.07-0.1)	0.3 (0.1-0.6) *	0.4 (0.1-0.6) *	<0.01
Aldosterone (pg/mL)	69.6 (63.5-73.0)	67.5 (42.5-114.5)	98 (60.7-176.9) *#	<0.01
Aldosterone/renin	___	1.68 (0.77-4.92) (n=72)	3.99 (1.29-9.49) (n=17)	0.08

Data expressed as median (1st, 3rd quartiles). NT= normotensive; HT= non-resistant hypertensive; RH = resistant hypertensive; LDL = low-density lipoprotein; HDL = high-density lipoprotein; HbA1c = glycated hemoglobin. * p<0.05 vs NT ; p< 0.05 # vs HT






β-blockers (%)                                                            	14	68	<0.01
ACE inhibitors 	17	38	<0.01
Angiotensin receptor blocker (%)	73	55	<0.01








Table 4 - MMP-2, TIMP-2 e MMP-2/TIMP-2 correlation with target organ damage in resistant hypertension
	MMP-2 r (p-value)	TIMP-2 r (p-value)	MMP-2/TIMP-2r (p-value)
PWV	0.02 (0.81)	-0.005 (0.95)	0.01 (0.92)
LVMI	0.10 (0.30)	0.17 (0.07)	-0.05 (0.62)




Table 5 - MMP-2, TIMP-2 e MMP-2/TIMP-2 correlation with target organ damage in non-resistant hypertension
	MMP-2 r (p-value)	TIMP-2 r (p-value)	MMP-2/TIMP-2 r (p-value)
PWV	-0.15 (0.10)	-0.15 (0.11)	0.07 (0.46)
LVMI	-0.01 (0.93)	-0.09 (0.34)	0.05 (0.61)




Table 6 - MMP-2, TIMP-2 e MMP-2/TIMP-2 correlation with target organ damage in resistant and non-resistant hypertension
	MMP-2 r (p-value)	TIMP-2 r (p-value)	MMP-2/TIMP-2 r (p-value)
PWV	-0.05 (0.42)	-0.09 (0.17)	0.06 (0.34)
LVMI	0.06 (0.34)	0.16 (0.02)	-0.09 (0.18)




Table 7 - Logistic regression for the presence of resistance to treatment*  
	 OR (95%CI) 	p-value 			 OR (95%CI) 	p-value 
Model 1:				Model 2:		
TIMP-2	1.03 (1.02-1.05)	<0.01		MMP-2/ TIMP-2	0.67 (0.51-0.87)	<0.01
BMI (kg/m²)	1.14 (1.07-1.22)	<0.01		BMI (kg/m²)	1.14 (1.07-1.21)	<0.01
Black race	3.54 (1.63-7.68) 	<0.01		Black race	3.92 (1.84-8.31) 	<0.01
*Adjusted for age, gender, aldosterone levels and presence of diabetes. The analysis was performed including resistant and non-resistant hypertension. 





